I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
MINERVA UROLOGICA E NEFROLOGICA
Rivista di Nefrologia e Urologia
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536
Minerva Urologica e Nefrologica 2015 December;67(4):365-74
Do diabetic patients receiving conventional dialysis solutions benefit from peritoneal dialysis?
Hassan K. 1, 2, Hassan F. 3, Hassan D. 4, Edgem R. 2, Hassan S. 5 ✉
1 Faculty of Medicine in the Galilee, Bar‑Ilan University, Safed, Israel;
2 Department of Nephrology and Hypertension, Peritoneal Dialysis Unit‑Western Galilee Hospital, Nahariya, Israel;
3 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;
4 Women’s Health Wing‑Western Galilee Hospital, Nahariya, Israel;
5 Department of Internal Medicine, Carmel Medical Center, Haifa, Israel
AIM: The study aimed to evaluate the impact of glucose-based peritoneal dialysis solutions (GBPDS) on diabetic patients on maintenance peritoneal dialysis.
METHODS: In this cross-sectional study we compared the influence of long term use of GBPDS on sixteen parameters related to the peritoneal glucose load, hydration status, inflammation, blood pressure, lipid profile and left ventricular mass in 45 stable PD patients (20 diabetic and 25 non-diabetic) receiving GBPDS.
RESULTS: At 24 months HbA1c, peritoneal glucose load index (PGLI), fluid overload (FO), plasma BNP, hsCRP and IL-6 levels, WBC count, blood pressure, triglycerides, LDL-C and left ventricular mass index (LVMI) were higher in diabetic patients compared to non-diabetic subjects (P≤0.04). Of 16 tested variables, 14 had deteriorated at 24 months in diabetic patients. PGLI values >3 g/kg/day or FO>1.0 L were associated with abnormal values of HbA1c, plasma BNP, CRP and plasma IL-6 levels. 60% of diabetic patients had PGLI>3g/kg/day compared to 32% of non-diabetic patients (P<0.001). Seventy per cent of diabetic patients had FO>1.0 L compared to 28% of non-diabetic patients (P<0.001). Only 12% of diabetic patients had nocturnal blood pressure dipping compared to 45% of non-diabetics (P=0.03). 57.8% of the studied patients had increased LVMI. Diabetic patients had higher LVMI values compared to non-diabetics (P<0.001). The presence of DM was found to be the most powerful predictor for the development of LVH (P< 0.001).
CONCLUSION:Utilization of GBPDS in diabetic PD patients may be associated with substantial adverse consequences affecting glycemic control, hydration status, lipid profile, inflammation, blood pressure control and LVM.